Frontiers in Medicine (Jan 2023)
Astatine-211 based radionuclide therapy: Current clinical trial landscape
- Per Albertsson,
- Per Albertsson,
- Tom Bäck,
- Karin Bergmark,
- Karin Bergmark,
- Andreas Hallqvist,
- Andreas Hallqvist,
- Mia Johansson,
- Mia Johansson,
- Emma Aneheim,
- Emma Aneheim,
- Sture Lindegren,
- Chiara Timperanza,
- Knut Smerud,
- Stig Palm
Affiliations
- Per Albertsson
- Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden
- Per Albertsson
- Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
- Tom Bäck
- Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
- Karin Bergmark
- Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden
- Karin Bergmark
- Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
- Andreas Hallqvist
- Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden
- Andreas Hallqvist
- Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
- Mia Johansson
- Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden
- Mia Johansson
- Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
- Emma Aneheim
- Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden
- Emma Aneheim
- Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
- Sture Lindegren
- Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
- Chiara Timperanza
- Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
- Knut Smerud
- Smerud Medical Research International AS, Oslo, Norway
- Stig Palm
- Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
- DOI
- https://doi.org/10.3389/fmed.2022.1076210
- Journal volume & issue
-
Vol. 9
Abstract
Astatine-211 (211At) has physical properties that make it one of the top candidates for use as a radiation source for alpha particle-based radionuclide therapy, also referred to as targeted alpha therapy (TAT). Here, we summarize the main results of the completed clinical trials, further describe ongoing trials, and discuss future prospects.
Keywords
